Pharmaceutical Co., Ltd. is an A-share company listed at Shenzhen Stock
Exchange. Abbreviation of the security is Yifan Pharmaceutical while the
security code is 002019.
one pharmaceutical enterprise focusing on innovation, R&D and
manufacturing, Yifan Pharmaceutical has the Yifan Research Institute, a
national post-doctoral research station and a enterprise technology center
(R&D center) at provincial level. With several high-tech enterprises, Yifan
now has more than 100 masters and doctors majored in pharmacy and related
fields, owns two advanced biologics innovation R&D platforms with DiKineTM
and ITabTM, holds almost 100 international and domestic patent authorization,
among which, 35 are international patents.
has undertook National “Tenth Five-Year Plan” Key Projects, National High-tech
Industrialization Demonstration Projects and National Torch Projects, and has
obtained the second prize for State Invention Award and National Prize for
Progress in Science and Technology respectively.
by expertise, specialization and product portfolio in target therapeutic areas
as guidance, Yifan has continuously innovating, transformatively upgrading,
focusing on macromolecular biologics, high-end chemical drug, special
Traditional Chinese Medicine and other key therapeutic areas. Dozens of
high-end chemical drugs are under development, and ten of them are at clinical
or ANDA application stages, and Yifan holds over 400 approval numbers for
marketing of drugs in therapeutic areas of gynecology, pediatrics, dermatology
and etc. 40 of these drugs are exclusive to the company, and 20 of which are
covered by national health insurance. Several macromolecule biological drugs
are in global phase II and III studies. As one Chinese enterprise first having macromolecule
innovative drugs for phase II and III clinical testing in America,Yifan will
lead Chinese biologics to knock on America’s door.
has already formed the manufacturing center of high-end chemical drug and herbal
products in Anhui Province, manufacturing center of dermatological and
gynecological products in Sichuan Province, manufacturing center of orthopedics
drug and therapeutic infusion center in Liaoning Province, R&D center and
manufacturing centers of macromolecule biologics in Beijing and Shanghai and
API manufacturing center in Zhejiang.
business of Yifan has covered all provinces and cities but Hong Kong SAR, Macau
SAR and Taiwan, and the coverage rate of pharmaceutical preparations in
second-class hospitals in China exceeding 60%. Meanwhile, as one of the largest
manufacturer and supplier of pantothenic acid and Provitamin B5, the sales
network of API of Yifan has radiated many countries and regions in Europe, US and
etc, and has leading the global market with the market share is 40% -45%.
the future, Yifan will constantly focus on pharmaceutical and healthcare
industry, adhere to the development strategy of “integration, innovation, and
globalization”, abide by the core value of “pragmatism,
innovation, honesty and diligence”, commit to bring benefits to customers,
build development platform for employee, achieve wealth for shareholders,
create value for society, and continue to grow as the expert in global
pharmaceutical and healthcare industry.